Switzerland

1 compound entry is recorded for this jurisdiction. A compound absent from this page has no verified entry here, which means the position has not been established from a primary source — not that no position exists.

Retatrutide
Investigational — no marketing authorisation · Swissmedic
Not authorised. Swissmedic has stated that the substance is still in clinical development and is not authorised internationally, while noting that it is already available on the black market.
Swissmedic warning regarding GLP-1 products · verified 2026-07-30

Scope of this reference

This knowledge base is scientific and regulatory reference material for businesses. It is not medical advice, not a recommendation, and not product promotion. Regulatory classification differs by jurisdiction, by form and by route of administration, and a statement recorded for one territory does not describe the position in another.

HelixEVO does not supply medicinal products for human administration. Material is supplied to businesses for research and manufacturing purposes only. Where a compound holds no marketing authorisation, human administration outside an authorised clinical trial is not a lawful supply route.

Every regulatory and analytical statement carries its source and the date it was last verified. Where a value could not be established from a primary source it is recorded as unverified rather than estimated.

Switzerland

Retatrutide